{"id":57504,"date":"2024-07-23T00:03:56","date_gmt":"2024-07-23T00:03:56","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2024\/07\/23\/radical-catheter-technologies-presents-analysis-of-disruptive-recently-fda-cleared-endovascular-technology-at-the-society-of-neurointerventional-surgery-snis-21st-annual-meeting\/"},"modified":"2024-07-23T00:03:56","modified_gmt":"2024-07-23T00:03:56","slug":"radical-catheter-technologies-presents-analysis-of-disruptive-recently-fda-cleared-endovascular-technology-at-the-society-of-neurointerventional-surgery-snis-21st-annual-meeting","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/radical-catheter-technologies-presents-analysis-of-disruptive-recently-fda-cleared-endovascular-technology-at-the-society-of-neurointerventional-surgery-snis-21st-annual-meeting\/","title":{"rendered":"Radical™ Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery (SNIS) 21st Annual Meeting"},"content":{"rendered":"
\n

Company Simultaneously Announces Close of $20 Million Financing Round, US FDA 510(k) Clearance of Neurovascular Radical Catheter and Initial Post-Market Clinical Experience<\/em><\/p>\n

CAMPBELL, Calif., July 22, 2024 (GLOBE NEWSWIRE) — Radical™ Catheter Technologies<\/a>, a medical device company pioneering the next generation of endovascular access and delivery products, today announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) for Radical Catheter, the first significant advance in catheter technology in more than three decades. This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery (SNIS) 21st<\/sup> annual meeting<\/a>. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors (NTI)<\/a>, which will be used to scale the company and expand the Radical platform.<\/p>\n

\u201cWhile catheters are the foundation of every neurovascular procedure I perform, current gaps in catheter technology fundamentally limit complex life-saving procedures. The operators in this pilot experience consistently commented on a number of advantages to the Radical Catheter, including greater flexibility to access targeted areas, more stability and increased durability,\u201d said Christopher Kellner, MD, cerebrovascular neurosurgeon, Mount Sinai Health System, while presenting the initial clinical analysis. \u201cIn our initial case series, the Radical catheter consistently reached further territories of the brain than we are accustomed to with conventional catheters. With this dramatically better performance, I expect to be able to more easily address complex procedures.\u201d<\/p>\n

The analysis evaluated a wide array of neuroendovascular procedures including treatments for aneurysms and stroke that were performed by 14 operators across six hospitals in four institutions, consisting of Cleveland Clinic, Mount Sinai Health System, Prisma Health and University at Buffalo. Findings indicate that Radical Catheter demonstrated best-in-class performance, including:<\/p>\n